
WHO AMR Products Data Analysis

Distributions of product type

Non-traditional: 286 (42.8%)

Antibiotics: 383 (57.2%)




2 **Distributions of R&D phase**

Phase I :- 310 (46.3%)

Phase II:- 186 (27.8%)


Phase III:-146 (21.8%)

Preregistration :- 27 (4.04%)




Top Antibacterial Class

Bacteriophage



Top Indication

Gram negative infection



5 **Top developers**

Qpex GSK

